Key Takeaways The study showed Pyrukynd met its hemoglobin endpoint but missed its goal of reducing pain crises.AGIO reported mixed secondary results, with gains in hemoglobin and bilirubin but no fatigue improvement.Agios plans a regulatory filing in early 2026, citing clearer benefits in hemoglobin responders.Shares of Agios Pharmaceuticals (AGIO) tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying RCEL stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at $23 per share, which translates to a market cap valuation of ~$1.4bn.Edmund Ingham ...

Core Points - The conference call is focused on the top line results from the pivotal Phase III RISE UP trial of mitapivat for treating sickle cell disease [2] - The call includes key executives from Agios Pharmaceuticals, indicating a comprehensive discussion on the trial results and future implications [4] Company Overview - Agios Pharmaceuticals is actively engaging with investors to discuss significant trial outcomes, showcasing its commitment to transparency and investor relations [2][4] - The company is preparing to share detailed findings from the RISE UP trial, which is crucial for its product pipeline and market strategy [2] Industry Context - The Phase III RISE UP trial represents a critical step in the development of treatments for sickle cell disease, a condition with significant unmet medical needs [2] - The results from this trial could have implications for the broader pharmaceutical industry, particularly in the area of rare diseases and innovative therapies [2]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index falling approximately 0.2% while NASDAQ and S&P 500 saw slight gains of 0.19% and 0.08% respectively [1] - Communication services sector rose by 0.8%, while energy stocks declined by 1.6% [1] Company Performance - Lowe's Companies, Inc. (NYSE:LOW) shares increased over 5% after exceeding Wall Street profit expectations for Q3, reporting adjusted earnings per share of $3.06, a 5.9% year-over-year increase, surpassing the consensus estimate of $2.97 [2][3] - The company slightly missed sales expectations but raised its full-year revenue target, focusing on professional customers and online growth [2] Commodity Market - Oil prices fell by 2.4% to $59.26, while gold prices increased by 0.3% to $4,077.20 [6] - Silver and copper also saw gains, with silver up 0.2% to $50.615 and copper rising 0.4% to $4.9945 [6] Stock Volatility - WeShop Holdings Limited (NASDAQ:WSHP) shares surged 413% to $169.32 following its Nasdaq debut [8] - Freight Technologies, Inc. (NASDAQ:FRGT) shares rose 67% to $1.1045 after launching its AI-powered freight rate prediction platform [8] - Semrush Holdings, Inc. (NYSE:SEMR) shares increased by 74% to $11.79 after Adobe announced acquisition plans [8] - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares dropped 50% to $22.88 due to Phase 3 trial results not meeting statistical significance [8] - Carver Bancorp, Inc. (NASDAQ:CARV) shares fell 51% to $1.4702 after announcing plans to de-register its common stock [8] - Tempest Therapeutics, Inc. (NASDAQ:TPST) shares decreased by 47% to $4.94 following an acquisition announcement [8] International Markets - European shares mostly declined, with the eurozone's STOXX 600 down 0.03% and major indices like London's FTSE 100 and Germany's DAX 40 also falling [7] - Asian markets closed mixed, with Japan's Nikkei 225 and Hong Kong's Hang Seng both down, while China's Shanghai Composite and India's BSE Sensex gained [9] Economic Indicators - U.S. crude oil inventories decreased by 3.426 million barrels, significantly more than the expected 0.6 million [12] - U.S. exports rose by $0.2 billion to $280.8 billion, while imports fell by 5.1% to $340.4 billion, leading to a reduced trade deficit of $59.6 billion [12]

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.AGIO is testing key support levels. See what the experts say hereThe trial met its primary endpoint of hemoglobin response, with mitapivat demonstrating a statistically significant improvement compared to placebo.Also Read: FDA Delays Decision On Agios Pharmaceuticals’ Blood Disorder Drug For Expanded UseDataWhile mitapivat also showed ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Agios Pharmaceuticals (NasdaqGS:AGIO) Update / Briefing November 19, 2025 08:00 AM ET Company ParticipantsEllen Horste - Equity Research AssociateSarah Gheuens - Chief Medical Officer and Head of Research and DevelopmentBrian Goff - CEOMorgan Sanford - Head of Investor RelationsBiree Andemariam - Professor of MedicineConference Call ParticipantsTessa Romero - Senior Analyst of Biotechnology Equity ResearchEmily Bodnar - Biotech Equity Research AnalystEric Smith - Senior Biotechnology AnalystLuca Issi - Seni ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction... ...

Forward-looking statements Topline results Phase 3 RISE UP in sickle cell disease November 19, 2025 This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat; Agios' plans for future meetings with, or submissions to, regulators, including the FDA; Agios' plans for the development of mitapivat, t ...